Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical...
Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date B...
Cutting-edge technology now available in Mobius® 3D process containers Provides 10 times greater abrasion resistance compared to other single-use bi...
Triple quadrupole mass spectrometers (LC/MS/MS) are established in labs dealing with challenging matrices, as they offer very low detection limits with spe...
The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial olig...
The expansion project aims to (i) grow Virica’s bioprocessing capacity to keep pace with client demand for scaling up viral medicines, (ii) advance n...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applyin...
Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced the o...
Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development. On ...
The first study presents a new cell-based assay called TAgmentation of Prime Editor sequencing (TAPE-seq) that can predict genome-wide off-target candidate...
The partnership reinforces Flare's commitment to longitudinal testing, leveraging Caris' comprehensive molecular tissue and liquid profiling services inclu...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer ...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sy...
© 2024 Biopharma Boardroom. All Rights Reserved.
